|
|
Volumn 60, Issue 5, 2005, Pages 307-309
|
|
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer: Commentary
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANASTROZOLE;
AROMATASE INHIBITOR;
RALOXIFENE;
SELECTIVE ESTROGEN RECEPTOR MODULATOR;
TAMOXIFEN;
ADJUVANT THERAPY;
ARTHRALGIA;
BREAST CANCER;
CANCER RECURRENCE;
CANCER RISK;
CLINICAL TRIAL;
COMPARATIVE STUDY;
CONFIDENCE INTERVAL;
DRUG EFFICACY;
DRUG TOLERABILITY;
ENDOMETRIUM CANCER;
HEALTH HAZARD;
HUMAN;
METASTASIS;
MORTALITY;
NOTE;
OSTEOLYSIS;
OSTEOPENIA;
OSTEOPOROSIS;
POSTMENOPAUSE;
PREVALENCE;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
RISK REDUCTION;
SIDE EFFECT;
SURVIVAL RATE;
|
|
EID: 17644417091
PISSN: 00297828
EISSN: None
Source Type: Journal
DOI: 10.1097/01.ogx.0000160573.78426.6a Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|